Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Personalized versus standard-dose IgM-enriched immunoglobulin in septic shock
2018-001613-33Phase 3Active
- Sponsor
- Azienda Ospedaliera Universitaria Policlinico
- Start
- Jun 2021
- Modality
- Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of IgM-enriched polyclonal immunoglobulin in septic shock (2 arms), sponsored by Azienda Ospedaliera Universitaria Policlinico. Primary endpoint: All-cause mortality at day 28 after randomization. Started Jun 2021; status: active.
02
Drugs
IgM-enriched polyclonal immunoglobulin
03
Conditions
septic shock
Beyond the preview
Go deeper on 2018-001613-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001613-33.